EP2968317A4 - TARGETING THE mTOR PATHWAY IN NEUROLOGICAL DISEASE - Google Patents
TARGETING THE mTOR PATHWAY IN NEUROLOGICAL DISEASEInfo
- Publication number
- EP2968317A4 EP2968317A4 EP14762460.5A EP14762460A EP2968317A4 EP 2968317 A4 EP2968317 A4 EP 2968317A4 EP 14762460 A EP14762460 A EP 14762460A EP 2968317 A4 EP2968317 A4 EP 2968317A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- targeting
- neurological disease
- mtor pathway
- mtor
- pathway
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361794606P | 2013-03-15 | 2013-03-15 | |
US201361852150P | 2013-03-15 | 2013-03-15 | |
US201361803977P | 2013-03-21 | 2013-03-21 | |
US201361918307P | 2013-12-19 | 2013-12-19 | |
PCT/US2014/030693 WO2014145857A1 (en) | 2013-03-15 | 2014-03-17 | TARGETING THE mTOR PATHWAY IN NEUROLOGICAL DISEASE |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2968317A1 EP2968317A1 (en) | 2016-01-20 |
EP2968317A4 true EP2968317A4 (en) | 2016-12-28 |
Family
ID=51538117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14762460.5A Ceased EP2968317A4 (en) | 2013-03-15 | 2014-03-17 | TARGETING THE mTOR PATHWAY IN NEUROLOGICAL DISEASE |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2968317A4 (en) |
WO (1) | WO2014145857A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2726108B1 (en) | 2011-06-29 | 2018-01-10 | The Trustees of Columbia University in the City of New York | Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction |
CN104829610B (en) * | 2014-06-20 | 2017-03-15 | 中国科学院合肥物质科学研究院 | A kind of novel cloth Shandong tyrosine kinase inhibitor |
CN112237629A (en) * | 2019-07-16 | 2021-01-19 | 温州市中心医院 | Application of ERK/mTOR signal pathway regulator in preparing medicine for improving or treating neurodevelopmental disorder related diseases |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062681A2 (en) * | 2008-10-30 | 2010-06-03 | University Of South Florida | Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism |
US20100298304A1 (en) * | 2009-01-16 | 2010-11-25 | Massachusetts Institute Of Technology | Diagnosis and treatment of autism spectrum disorders |
CN102488687A (en) * | 2011-12-22 | 2012-06-13 | 武汉大学 | Application of rapamycin to preparation of medicament for treating schizophrenia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE033894T2 (en) * | 2006-08-23 | 2018-01-29 | Kudos Pharm Ltd | 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
EP2456869A4 (en) * | 2009-07-23 | 2013-11-27 | Trustees Of The University Of Princeton | Inhibitors of mtor kinase as anti-viral agents |
-
2014
- 2014-03-17 WO PCT/US2014/030693 patent/WO2014145857A1/en active Application Filing
- 2014-03-17 EP EP14762460.5A patent/EP2968317A4/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062681A2 (en) * | 2008-10-30 | 2010-06-03 | University Of South Florida | Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism |
US20100298304A1 (en) * | 2009-01-16 | 2010-11-25 | Massachusetts Institute Of Technology | Diagnosis and treatment of autism spectrum disorders |
CN102488687A (en) * | 2011-12-22 | 2012-06-13 | 武汉大学 | Application of rapamycin to preparation of medicament for treating schizophrenia |
Non-Patent Citations (10)
Title |
---|
ATSUSHI SATO ET AL: "Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex", NATURE COMMUNICATIONS, vol. 3, 18 December 2012 (2012-12-18), United Kingdom, pages 1292, XP055320205, ISSN: 2041-1723, DOI: 10.1038/ncomms2295 * |
DELIA M. TALOS ET AL: "The Interaction between Early Life Epilepsy and Autistic-Like Behavioral Consequences: A Role for the Mammalian Target of Rapamycin (mTOR) Pathway", PLOS ONE, vol. 7, no. 5, 2 May 2012 (2012-05-02), pages e35885, XP055320394, DOI: 10.1371/journal.pone.0035885 * |
GARCÍA-ECHEVERRÍA CARLOS: "Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 15, 2010, pages 4308 - 4312, XP028851573, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2010.05.099 * |
JULIE MEFFRE ET AL: "5-HT 6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia", EMBO MOLECULAR MEDICINE, vol. 4, no. 10, 1 October 2012 (2012-10-01), Weinheim, pages 1043 - 1056, XP055285724, ISSN: 1757-4676, DOI: 10.1002/emmm.201201410 * |
KER YU ET AL: "Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 70, no. 2, 15 January 2010 (2010-01-15), pages 621 - 631, XP002646841, ISSN: 0008-5472, [retrieved on 20100112], DOI: 10.1158/0008-5472.CAN-09-2340 * |
PETER T. TSAI ET AL: "Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice", NATURE, vol. 488, no. 7413, 1 July 2012 (2012-07-01), United Kingdom, pages 647 - 651, XP055320065, ISSN: 0028-0836, DOI: 10.1038/nature11310 * |
Q. LIU ET AL: "Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR", CANCER RESEARCH, vol. 73, no. 8, 22 February 2013 (2013-02-22), US, pages 2574 - 2586, XP055286271, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-1702 * |
See also references of WO2014145857A1 * |
THEOHARIDES THEOHARIS C: "Is a Subtype of Autism an Allergy of the Brain?", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 35, no. 5, 27 April 2013 (2013-04-27), pages 584 - 591, XP028543857, ISSN: 0149-2918, DOI: 10.1016/J.CLINTHERA.2013.04.009 * |
ZHOU MIOU ET AL: "mTOR Inhibition Ameliorates Cognitive and Affective Deficits Caused by Disc1 Knockdown in Adult-Born Dentate Granule Neurons", NEURON, CELL PRESS, US, vol. 77, no. 4, 20 February 2013 (2013-02-20), pages 647 - 654, XP028983424, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2012.12.033 * |
Also Published As
Publication number | Publication date |
---|---|
EP2968317A1 (en) | 2016-01-20 |
WO2014145857A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3003473T3 (en) | Topical neurological stimulation | |
HK1219663A1 (en) | Drug combinations | |
HK1220263A1 (en) | Multi-purposed self-propelled device | |
SG11201508648XA (en) | Flow pathway subassembly | |
HRP20180684T1 (en) | Drug combination | |
HK1222118A1 (en) | Imaging neurological disease | |
AU350549S (en) | Breathalyzer | |
EP2983648A4 (en) | Combination therapeutic nanoparticles | |
GB201318625D0 (en) | Seat 11 | |
GB201308440D0 (en) | Therapeutic | |
GB201318668D0 (en) | Sonosensitive therapeutic | |
EP2968317A4 (en) | TARGETING THE mTOR PATHWAY IN NEUROLOGICAL DISEASE | |
GB2514124B (en) | Turf Treatment | |
Upson | HEALTHY SKEPTICISM | |
AU5377P (en) | Suncalred Calibrachoa hybrid | |
AU5378P (en) | Suncallemon Calibrachoa hybrid | |
AU4979P (en) | USCAL5302M Calibrachoa hybrid | |
AU4978P (en) | USCAL91001 Calibrachoa hybrid | |
GB201306246D0 (en) | Ball maker | |
GB201307345D0 (en) | X-system 6 | |
GB201201138D0 (en) | Neurological therapies | |
GB201316435D0 (en) | Seat 10 | |
GB201314858D0 (en) | Seat 8 | |
GB201314440D0 (en) | Seat 7 | |
GB201314096D0 (en) | Seat 6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150923 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/497 20060101AFI20160727BHEP Ipc: A61K 31/519 20060101ALI20160727BHEP Ipc: A61P 25/00 20060101ALN20160727BHEP Ipc: A61K 31/4745 20060101ALI20160727BHEP Ipc: C07D 471/04 20060101ALI20160727BHEP Ipc: A61P 25/24 20060101ALN20160727BHEP Ipc: A61K 31/5377 20060101ALI20160727BHEP Ipc: A61P 25/18 20060101ALN20160727BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20161128 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/24 20060101ALN20161122BHEP Ipc: A61K 31/497 20060101AFI20161122BHEP Ipc: C07D 471/04 20060101ALI20161122BHEP Ipc: A61P 25/00 20060101ALN20161122BHEP Ipc: A61K 31/5377 20060101ALI20161122BHEP Ipc: A61K 31/4745 20060101ALI20161122BHEP Ipc: A61K 31/519 20060101ALI20161122BHEP Ipc: A61P 25/18 20060101ALN20161122BHEP |
|
17Q | First examination report despatched |
Effective date: 20180810 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20201009 |